Skip to main content
Premium Trial:

Request an Annual Quote

Wider Boosters Expected in US

The US Food and Drug Administration may authorize booster doses of the Pfizer-BioNTech SARS-CoV-2 vaccine for all adults as early as Thursday, the New York Times reports. It adds that the Centers for Disease Control and Prevention may also weigh in on Friday, which could allow broader booster vaccinations to begin.

FDA previously authorized Pfizer-BioNTech SARS-CoV-2 vaccine boosters in September for individuals 65 years old or older and younger individuals at increased risk of developing severe disease. The companies said last week that they were seeking an expansion of that booster eligibility to all adults.

As the Times notes, some spots in the US like New York City, California, and Colorado have already moved to expand booster access, as the expanded authorization is widely expected and as there is increased demand before the holiday season.

Recent data from Pfizer and BioNTech indicates that a third dose increases protection against symptomatic disease to about 95 percent, NPR adds.

Moderna is also expected to also seek an expansion to its booster authorization, according to the Times.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.